Physician profile
David Jakubowicz
NPI 1538169230
$2,630.48
in general payments reported to CMS, 2019-2025
17 companies · $1,044 in 2025
The $1,044 reported for 2025 was more than what 80% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $704 · 2020: $81.09 · 2022: $370 · 2023: $197 · 2024: $234 · 2025: $1,044.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,232 · Travel and Lodging: $243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,232.45 |
| Travel and Lodging | $243.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerin Medical INC. | $965.90 | 2019-2025 | |
| Stryker Corporation | $397.69 | 2019 | |
| Pfizer INC. | $343.18 | 2019-2025 | |
| Glaxosmithkline, LLC. | $187.57 | 2022-2023 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $129.59 | 2019-2022 | |
| Abbvie INC. | $126.27 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.59 | 2019 | |
| Phadia US INC. | $85.35 | 2022 | |
| Alk-Abello, INC | $64.55 | 2019 | |
| Genzyme Corporation | $42.43 | 2022-2023 | |
| Optinose US, INC. | $36.69 | 2020-2024 | |
| Regeneron Healthcare Solutions, INC. | $34.81 | 2023 | Dupixent |
| Merck Sharp & Dohme LLC | $33.06 | 2020-2023 | Verquvo, Belsomra |
| Axsome Therapeutics, INC. | $30.07 | 2025 | Symbravo |
| Medtronic, INC. | $24.92 | 2023 | Propel |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $16.38 | 2022 | |
| Phathom Pharmaceuticals, INC. | $15.43 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Jakubowicz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.